Literature DB >> 1693295

Effects of recombinant human granulocyte colony-stimulating factor (CSF), human granulocyte macrophage-CSF, and gibbon interleukin-3 on hematopoiesis in human long-term bone marrow culture.

L H Coutinho1, A Will, J Radford, R Schiró, N G Testa, T M Dexter.   

Abstract

We have studied the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF), hG macrophage-CSF (hGM-CSF), and gibbon interleukin-3 (gIL-3) on cell proliferation and differentiation in human long-term bone marrow culture (LTBMC). hG-CSF induced a maximal increase of 2.3-fold in both total nonadherent cells and GM cluster-forming cells, but only an increase of 1.7-fold in GM-colony-forming cell (GM-CFC) numbers, influencing mainly neutrophil differentiation. Cultures treated with hGM-CSF demonstrated a peak of 12.8-, 21- and 3.2-fold elevations in total nonadherent cells, cluster, and GM-CFC, respectively, and influenced differentiation of neutrophils, monocytes, eosinophils, and lymphocytes. Cultures treated with gIL-3 demonstrated the largest expansion in the GM-CFC population, reaching a maximum of 5.3-fold in relation to that of unstimulated controls. IL-3 treatment also increased the numbers of GM clusters and mature cells (including all myeloid cells and lymphocytes) 7.8- and 4.8-fold, respectively. Similar quantitative and qualitative changes were induced by G-CSF, GM-CSF, and IL-3 in LTBMCs of patients in remission after treatment for acute lymphoblastic leukemia or Hodgkin's lymphoma. Overall, the expansion of GM progenitor cells in cultures treated with growth factors was larger in the adherent cell layer than in the nonadherent cell fraction. In addition, hGM-CSF, gIL-3, and hG-CSF to a less extent, increased the cycling rates of GM-CFC progenitors located in the adherent layer. These results indicate that hG-CSF is a much less potent stimulus of hematopoiesis in LTBMC than the other CSFs assayed, and that the increases in cell production after treatment with G-CSF, GM-CSF, or IL-3 may be achieved by primary expansion of different cell populations within the hierarchy of the hematopoietic system. The effects of the growth factors were transient and the longevity of hematopoiesis in the cultures was not altered, suggesting that treatment with IL-3, GM-CSF, or G-CSF had not compromised the ability of primitive cells to give rise to mature cells. This indicates that the stromal microenvironment in LTBMC can override potential differentiation-inducing activities of the CSFs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1693295

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Combination of recombinant cytokines fails to produce ex vivo expansion of human blood hematopoietic progenitor cells.

Authors:  Y Takaue; T Abe; Y Kawano; A Hirao; A Yokobayashi; Y Okamoto; S Saito; T Shimizu; J Sato; T Watanabe
Journal:  Ann Hematol       Date:  1992-05       Impact factor: 3.673

2.  Rapid medium perfusion rate significantly increases the productivity and longevity of human bone marrow cultures.

Authors:  R M Schwartz; B O Palsson; S G Emerson
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

3.  Differential effects of microenvironmentally presented interleukin 3 versus soluble growth factor on primitive human hematopoietic cells.

Authors:  T Otsuka; J D Thacker; C J Eaves; D E Hogge
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

4.  Proliferation of human progenitor cells in a long-term culture system is more efficiently sustained by the addition of Flt-3 ligand or megakaryocyte growth and development factor than by Kit ligand.

Authors:  G Cartron; C Binet; O Hérault; C Cailliot; M C Bernard; M H Estienne; N Clément; Ph Colombat; J Domenech
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 5.  The role of CD40/CD40 ligand interactions in bone marrow granulopoiesis.

Authors:  Irene Mavroudi; Helen A Papadaki
Journal:  ScientificWorldJournal       Date:  2011-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.